FY2028 EPS Estimates for Prothena Increased by HC Wainwright

Prothena Co. plc (NASDAQ:PRTA - Free Report) - Research analysts at HC Wainwright lifted their FY2028 earnings estimates for shares of Prothena in a note issued to investors on Wednesday, November 13th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will post earnings of $3.34 per share for the year, up from their prior estimate of $3.26. HC Wainwright has a "Buy" rating and a $84.00 price objective on the stock. The consensus estimate for Prothena's current full-year earnings is ($2.34) per share.

Prothena (NASDAQ:PRTA - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($1.10) EPS for the quarter, topping analysts' consensus estimates of ($1.18) by $0.08. Prothena had a negative net margin of 98.86% and a negative return on equity of 24.19%. The company had revenue of $0.97 million during the quarter, compared to the consensus estimate of $1.22 million. During the same period in the prior year, the business posted $0.38 EPS. The company's quarterly revenue was down 98.9% on a year-over-year basis.

Other equities analysts have also recently issued reports about the stock. Royal Bank of Canada reduced their price objective on shares of Prothena from $28.00 to $24.00 and set a "sector perform" rating for the company in a research report on Friday, August 9th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Prothena in a research note on Monday, September 30th. StockNews.com upgraded shares of Prothena from a "sell" rating to a "hold" rating in a research report on Monday, August 12th. Oppenheimer reduced their price objective on Prothena from $66.00 to $62.00 and set an "outperform" rating for the company in a report on Wednesday, August 14th. Finally, Bank of America lowered their target price on Prothena from $33.00 to $31.00 and set a "neutral" rating on the stock in a research note on Tuesday, October 1st. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $61.86.

Prothena Trading Down 13.0 %

Shares of PRTA traded down $2.09 during mid-day trading on Friday, reaching $14.01. The company's stock had a trading volume of 759,611 shares, compared to its average volume of 582,568. The stock has a market cap of $753.46 million, a P/E ratio of -5.97 and a beta of 0.16. Prothena has a 1-year low of $14.00 and a 1-year high of $41.54. The business has a 50-day simple moving average of $18.32 and a two-hundred day simple moving average of $20.38.

Hedge Funds Weigh In On Prothena

A number of hedge funds have recently added to or reduced their stakes in PRTA. Signaturefd LLC grew its holdings in shares of Prothena by 182.1% during the 2nd quarter. Signaturefd LLC now owns 1,337 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 863 shares in the last quarter. Headlands Technologies LLC acquired a new stake in Prothena during the first quarter worth about $96,000. China Universal Asset Management Co. Ltd. increased its holdings in Prothena by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,344 shares of the biotechnology company's stock valued at $173,000 after buying an additional 4,026 shares during the period. Intech Investment Management LLC acquired a new position in shares of Prothena in the 3rd quarter valued at approximately $210,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Prothena by 13.1% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,236 shares of the biotechnology company's stock worth $211,000 after acquiring an additional 1,186 shares during the period. Institutional investors own 97.08% of the company's stock.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.